Private Advisor Group LLC purchased an additional 261 shares of
IDEXX Laboratories, Inc. as the company continues to demonstrate strong
growth and solid instrument placement on a global scale. The company outperformed competitors in
trading and has been upgraded to \"Buy\" by
StockNews.com. Additionally, IDEXX is scheduled to present at the
Stifel Conference and announced their 2024 Investor Day. Despite a price target cut by
Morgan Stanley, those who invested in IDEXX five years ago have seen a 143% increase. Insider shares are being sold, implying mixed insider sentiment. However, the company recently rebounded from significant drawdowns and is witnessing improving operating margins. Meanwhile, the company posted stronger than expected Q3 earnings but slashed its 2024 view.
Leadership transitions have been seen and IDEXX's balance sheet remains solid. Looking ahead, the
aging pet population presents a 'solid longer-term tailwind' for IDEXX Labs. Lastly, the company continues its streak of innovation with the announcement of their revolutionary
slide-free cellular analyzer, IDEXX inVue Dx™, aiming to transform in-clinic workflows.
Idexx Laboratories IDXX News Analytics from Fri, 08 Sep 2023 07:00:00 GMT to Thu, 16 May 2024 10:08:35 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -4
